Effect of new breakpoints proposed by Clinical and Laboratory Standards Institute in 2008 for evaluating penicillin resistance of Streptococcus pneumoniae in a Turkish University Hospital

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
Ozlem DoğanGülşen Hasçelik

Abstract

Clinical and Laboratory Standards Institute changed penicillin susceptibility breakpoints for Streptococcus pneumoniae in 2008. After reevaluation with new breakpoints, resistance rates decreased from 6.1% to 0.5% for nonmeningitis and increased from 6.6% to 33.3% for meningitis isolates in our hospital. This breakpoint modification is expected to reduce the inconsistency between susceptibility results and therapeutic outcomes; however, both the clinical microbiology laboratories and the clinicians should be aware of the change to interpret the susceptibility results.

References

Mar 18, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J P MetlayR F Breiman
Jul 20, 2002·The Lancet Infectious Diseases·Javier Garau
Jul 12, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Victor L YuUNKNOWN International Pneumococcal Study Group
May 4, 2004·The Journal of Laboratory and Clinical Medicine·Charles Feldman
Mar 16, 2005·Diagnostic Microbiology and Infectious Disease·Robertino M MeraAnthony R White
Dec 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lance R Peterson
Dec 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christine C Chiou
May 26, 2006·Antimicrobial Agents and Chemotherapy·Ricardo DiasManuela Caniça
Sep 28, 2006·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Robertino M MeraAnthony White
Jun 29, 2007·The Journal of Antimicrobial Chemotherapy·Burçin SenerJörg Sievers
Apr 15, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M Nowosiad, S Giedrys-Kalemba

❮ Previous
Next ❯

Citations

Jun 16, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M ImöhlM van der Linden
Nov 12, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Hakan ErdemHaluk Vahaboglu
Oct 10, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H Erdem, M Akova

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Meningitis (ASM)

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Bacterial Meningitis

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.